CDiddy, respectfully disagree. Covid WAS a bonus indication when we thought HIV BLA was around the corner. I would have considered it a bonus even when Cytodyn received the RTF as we were led to believe the delay was due to labeling and including more data from 700mg. NP clearly stated no additional trials were required.
Now Covid has become a crucial indication based on what we know today that the HIV BLA will require much more work and longer timeline with redoing receptor occupancy, etc.
For those jumping in the stock due to Covid, their investments were significantly de-risked due to HIV. That risk has gone up significantly IMO.